Edition:
India

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

2,570.00GBp
25 Sep 2020
Change (% chg)

29.00 (+1.14%)
Prev Close
2,541.00
Open
2,546.00
Day's High
2,570.00
Day's Low
2,518.00
Volume
233,274
Avg. Vol
1,193,738
52-wk High
2,698.00
52-wk Low
1,596.00

Summary

Name Age Since Current Position

Said Darwazah

62 2018 Executive Chairman of the Board

Sigurdur Olafsson

2018 Chief Executive Officer, Executive Director

Mazen Darwazah

61 2018 Executive Vice Chairman of the Board, President of MENA

Khalid Nabilsi

2011 Chief Financial Officer, Executive Director

Brian Hoffman

2017 President, US Generics Division

Riad Mishlawi

2018 President - Injectables

Bassam Wael Rushdi Kanaan

54 2018 Executive Vice President - Corporate Development and M&A

Majda Labadi

2018 Executive Vice President - Organisational Development

Henriette Nielsen

2018 Executive Vice President - Business Operations

Susan Ringdal

2020 Executive Vice President - Strategic Planning and Global Affairs

Shahin Fesharaki

2019 Chief Scientific Officer

Peter Speirs

2012 Company Secretary

Ali Al-Husry

62 2005 Non-Executive Director

Patrick Butler

59 2020 Senior Non-Executive Independent Director

John Castellani

69 2016 Non-Executive Independent Director

Nina Henderson

69 2016 Non-Executive Independent Director

Douglas Hurt

2020 Non-Executive Independent Director

Pamela Kirby

66 2014 Non-Executive Independent Director

Robert Pickering

60 2014 Senior Non-Executive Independent Director

Cynthia Schwalm

60 2019 Non-Executive Independent Director

Biographies

Name Description

Said Darwazah

Mr. Said Samih Darwazah serves as Executive Chairman of the Board of the Company. Said served as Chief Executive from July 2007 to February 2018 and has served as Chair since May 2014. Said has over 37 years of experience in numerous leadership roles at Hikma. Under Said’s leadership, Hikma has expanded into the US and become a leading player in injectables and the MENA region. Qualifications: Industrial Engineering degree from Purdue University, MBA from INSEAD.

Sigurdur Olafsson

Mr. Sigurdur Olafsson serves as Chief Executive Officer, Executive Director of the Company. Mr. Siggi has a wealth of international experience in the pharmaceutical industry, having held senior roles with Actavis Pharma Inc., Pfizer Inc. and Omega Farma. Siggi served as President and CEO of Global Generic Medicines at Teva Pharmaceuticals.

Mazen Darwazah

Mr. Mazen Samih Talib Darwazah serves as Executive Vice Chairman of the Board, President of MENA of the Company. Mazen has led and expanded the MENA region at Hikma. Since listing, he has Group level responsibility in his role as Executive Vice Chairman. Since 2014, he became responsible for the Group’s expansion into emerging markets. Qualifications: BA in Business Administration from the Lebanese American University, AMP from INSEAD.

Khalid Nabilsi

Mr. Khalid Nabilsi CPA serves as Chief Financial Officer, Executive Director of the Company. Mr. Khalid is responsible for Group finance, including reporting and capital management. Khalid has held several financial positions during 18 years with Hikma, including VP Finance. Qualifications: Certified Public Accountant. MBA from the University of Hull.

Brian Hoffman

Mr. Brian Hoffman serves as President, US Generics Division of the Company. Mr. Brian is responsible for all aspects of the Generics division in the US. Brian has significant strategic and operational experience from leadership roles at Hikma and prior consulting roles. Qualifications: BA in Business Administration from Boston University. MBA from the University of Chicago.

Riad Mishlawi

Mr. Riad Mishlawi serves as President - Injectables of the Company. Mr. Riad is responsible for all aspects of the Injectables division globally. Riad has significant pharmaceutical and operational experience from leadership roles at Hikma and Watson Pharmaceuticals. Qualifications: BSc in Engineering and a Master’s in Engineering and Management from George Washington University.

Bassam Wael Rushdi Kanaan

Mr. Bassam Wael Rushdi Kanaan CPA serves as Executive Vice President - Corporate Development and M&A of the Company. Bassam has Group level responsibility for strategic development, acquisitions and alliances. Bassam has held several executive positions during 18 years with Hikma, including Chief Financial Officer. Qualifications: US Certified Public Accountant and Chartered Financial Analyst. BA from Claremont McKenna. International Executive MBA from Kellogg/ Recanati Schools of Management.

Majda Labadi

Ms. Majda Labadi serves as Executive Vice President - Organisational Development of the Company. Majda has Group level responsibility for human resources. Majda has held several executive positions during 33 years with Hikma, including VP Injectables and VP MENA Operations. Qualifications: BA from the American University of Beirut. Master’s degree from Hochschule Fur Okonomie, Germany. Advanced Management Program at INSEAD.

Henriette Nielsen

Ms. Henriette Nielsen serves as Executive Vice President - Business Operations of the Company. Ms. Henriette leads the Group’s legal, compliance, risk, IT, business improvement, pharmacovigilance and digital functions. Qualifications: Law Degree from the University of Copenhagen. Master of Laws from the University of Edinburgh.

Susan Ringdal

Ms. Susan Ringdal serves as Executive Vice President - Strategic Planning and Global Affairs of the Company. Susan is responsible for strategic planning, investor relations, corporate affairs and business intelligence. Prior to joining Hikma, Susan worked for Alliance Unichem and Morgan Stanley. Qualifications: BA in History from Cornell University. MBA from London Business School.

Shahin Fesharaki

Mr. Shahin Fesharaki Ph.D. serves as Chief Scientific Officer of the Company. Mr. Shahin is responsible for all research and development activities in Hikma and has a strategic responsibility for enhancing Hikma’s product pipeline.

Peter Speirs

Mr. Peter Speirs serves as Company Secretary of the Company. Mr. Peter is responsible for advising on governance, executive remuneration, and listing related matters. Peter joined Hikma as Deputy Secretary and previously held roles with Barclays and Pool Re. Qualifications: Fellow of the Institute of Chartered Secretaries and Administrators. Law degree from the University of East Anglia.

Ali Al-Husry

Mr. Ali K. Al-Husry serves as Non-Executive Director of the Company. Mr. Ali held various management and leadership roles within Hikma before stepping into an advisory role in 1995, when he founded Capital Bank of Jordan, focusing on commercial and investment banking. Ali served as Chief Executive of Capital Bank until 2007. Qualifications: Mechanical Engineering degree from the University of Southern California, MBA from INSEAD.

Patrick Butler

Mr. Patrick Butler serves as Senior Non-Executive Independent Director of the Company. Mr. Pat was Senior Director at McKinsey & Co. During 25 years at McKinsey, he focused on strategic, financial and structuring advice to large corporations. Pat qualified in the audit and tax practice of Arthur Andersen. Qualifications: Chartered accountant. First-class honours degree in Commerce, postgraduate diploma in Accounting and Corporate Finance from University College Dublin.

John Castellani

Mr. John J. Castellani serves as Non-Executive Independent Director of the Company. John was President and Chief Executive Officer of Pharmaceutical Research and Manufacturers of America (PhRMA) and Business Roundtable. During his career John has also held senior positions with Burson-Marsteller, Tenneco, and General Electric. Qualifications: BSc in Biology from Union College Schenectady, New York.

Nina Henderson

Ms. Nina Henderson serves as Non-Executive Independent Director of the Company. Nina assumed Board-level responsibility for employee engagement in January 2019. Nina was Corporate VP of Bestfoods and President of Bestfoods Grocery prior to its acquisition by Unilever. During a 30-year career with Bestfoods, and its predecessor company CPC International, she held a wide variety of Global and North American executive general management and marketing positions. Nina has served as a director of Royal Dutch Shell, AXA Financial, The Equitable Companies, DelMonte, Pactiv and Walter Energy. Qualifications: Honours graduate and BSc from Drexel University.

Douglas Hurt

Mr. Douglas Malcolm Hurt serves as Non-Executive Independent Director of the Company. During his executive career, Douglas served as Finance Director of IMI plc, the global engineering group, from 2006 to 2015. Prior to this, he held a number of senior finance and general management positions at GlaxoSmithKline plc, which he joined in 1983, previously having worked at Price Waterhouse. His career has included several years working in the US as the Chief Financial Officer and significant experience in European businesses as an Operational and Regional Managing Director. Douglas is the Senior Independent Director and Chairman of the Audit Committee at Vesuvius PLC and Countryside Properties PLC. He is a non-executive director and Chairman of the Audit Committee of the British Standards Institution. Douglas served as Senior Independent Director and Chairman of the Audit Committee of Tate & Lyle plc until July 2019. Douglas is a Chartered Accountant and holds an MA(Hons) in Economics from Cambridge University.

Pamela Kirby

Dr. Pamela J. Kirby Ph.D. serves as Non-Executive Independent Director of the Company. Dr Kirby was Chief Executive of Quintiles Transnational Corp and held senior executive positions at F Hoffmann-La Roche and AstraZeneca. Previously, Dr Kirby chaired Scynexis, was Senior Independent Director of Informa and held non-executive positions with Smith & Nephew and Novo Nordisk. Qualifications: First-class BSc degree in Pharmacology, and Clinical Pharmacology PhD from the University of London.

Robert Pickering

Mr. Robert M. Pickering serves as Senior Non-Executive Independent Director of the Company. Mr. Robert became Senior Independent Director in May 2014. Robert was Chief Executive of Cazenove Group PLC and subsequently J.P. Morgan Cazenove until 2008. During 23 years at Cazenove and Co. he acquired extensive experience of the corporate and investment environment. Qualifications: Qualified solicitor with a law degree from Lincoln College, Oxford.

Cynthia Schwalm

Ms. Cynthia L. Schwalm is appointed as Non-Executive Independent Director effective 1 June 2019. Most recently, Cynthia was President and CEO of the North American divisions of the global pharmaceutical companies Ipsen and Eisai, and also held leadership positions at Amgen and Johnson & Johnson. Cynthia is a non-executive director of Caladrius Biosciences Inc., Kadman Group, and G1 Therapeutics Inc., where she chairs the Compensation Committee. She is a member of the National Association of Corporate Directors and an angel investment group associated with the University of North Carolina, and for nearly a decade she served on the Women's Leadership Advisory Board at Harvard University's Kennedy School of Government. Cynthia holds a BSN from the University of Delaware and EMBA from Wharton at the University of Pennsylvania.